Design of potent IGF1-R inhibitors related to bis-azaindoles

Chemical Biology and Drug Design

Volumn 76, Issue 2, 2010, Pages 100-106

  Nemecek, Conception ^a   Metz, William A ^a   Wentzler, Sylvie ^a   Ding, Fa Xiang ^a   Venot, Corinne ^a   Souaille, Catherine ^a   Dagallier, Anne ^a   Maignan, Sébastien ^a   Guilloteau, Jean Pierre ^a   Bernard, François ^a   Henry, Alain ^a   Grapinet, Sandrine ^a   Lesuisse, Dominique ^a  

^a SANOFI   (France)

Author keywords

drug discovery; enzyme structure; kinase; phosphatase; structure based drug design

Indexed keywords

INDOLE DERIVATIVE; PROTEIN KINASE SYK INHIBITOR; RECEPTOR BLOCKING AGENT; SOMATOMEDIN C RECEPTOR; INSULIN-LIKE GROWTH FACTOR-1, MOUSE; PROTEIN KINASE INHIBITOR; SOMATOMEDIN C;

ANIMAL CELL; ARTICLE; COMPUTER MODEL; CRYSTALLIZATION; DRUG BINDING; DRUG BIOAVAILABILITY; DRUG CLEARANCE; DRUG DESIGN; DRUG HALF LIFE; DRUG IDENTIFICATION; DRUG METABOLISM; DRUG POTENCY; DRUG SYNTHESIS; FEMALE; HIGH THROUGHPUT SCREENING; HUMAN; HUMAN CELL; MOUSE; NONHUMAN; PRIORITY JOURNAL; RAT; STRUCTURE ACTIVITY RELATION; ANIMAL; ANTAGONISTS AND INHIBITORS; BINDING SITE; CHEMISTRY; DRUG SCREENING; METABOLISM; SYNTHESIS; TUMOR CELL LINE; X RAY CRYSTALLOGRAPHY;

ANIMALS; BINDING SITES; CELL LINE, TUMOR; CRYSTALLOGRAPHY, X-RAY; DRUG DESIGN; DRUG SCREENING ASSAYS, ANTITUMOR; HUMANS; INDOLES; INSULIN-LIKE GROWTH FACTOR I; MICE; PROTEIN KINASE INHIBITORS; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 77954360109     PISSN: 17470277     EISSN: 17470285     Source Type: Journal    
DOI: 10.1111/j.1747-0285.2010.00991.x     Document Type: Article

References (25)

1. Kim J.J., Accili D., Naomi B. (2002) Signalling through IGF-I and insulin receptors: where is the specificity? Growth Horm IGF Res 12 : 84.
2. Furstenberger G., Senn H.-J. (2002) Insulin-like growth factors and cancer. Lancet Oncol 3 : 298.
3. Gross J.M., Yee D. (2003) The type-1 insulin-like growth factor receptor tyrosine kinase and breast cancer: Biology and therapeutic relevance. Cancer Metastasis Rev 22 : 327.
4. Yu H., Rohan T. (2000) Role of the insulin-like growth factor family in cancer development and progression. J Natl Cancer Inst 92 : 1472.
5. Bohula E.A., Playford M.P., Macaulay V.M. (2003) Targeting the type 1 insulin-like growth factor receptor as anti-cancer treatment. Anticancer Drugs 14 : 669.
6. Zhang H., Yee D. (2004) The therapeutic potential of agents targeting the type I insulin-like growth factor receptor. Expert Opin Investig Drugs 13 : 1569.
7. Gualberto A., Pollak M. (2009) Emerging role of insulin-like growth factor receptor inhibitors in oncology: early clinical trial results and future directions. Oncogene 28 : 3009.
8. Cox P.J., Majid T.N., Lai J.Y.Q., Morley A.D., Amendola S., Deprets S., Edlin C. (2001) Preparation of azaindoles as protein kinase inhibitors. PCT Int Appl 270 WO 03/000688 A1.
9. Wittman M., Carboni J., Attar R., Balasubramanian B., Balimane P., Brassil P., Beaulieu F. et al. (2005) Discovery of a 1H-Benzoimidazol-2-yl-1H- pyridin-2-one (BMS-536924) Inhibitor of Insulin-like Growth Factor I Receptor Kinase with in Vivo Antitumor Activity. J Med Chem 48 : 5639.
10. Yuen J.S.P., Macaulay V.M. (2008) Targeting the type 1 insulin-like growth factor receptor as a treatment for cancer. Expert Opin Ther Targets 12 : 589.
11. Garcia-Echeverria C., Pearson M.A., Marti A., Meyer T., Mestan J., Zimmermann J., Gao J. et al. (2004) In vivo antitumor activity of NVP-AEW541 as a novel, potent, and selective inhibitor of the IGF-IR kinase. Cancer Cell 5 : 231.
12. Ghose A.K., Herbertz T., Pippin D.A., Salvino J.M., Mallamo J.P. (2008) Knowledge Based Prediction of Ligand Binding Modes and Rational Inhibitor Design for Kinase Drug Discovery. J Med Chem 51 : 5149.
13. Munshi S., Kornienko M., Hall D.L., Reid J.C., Waxman L., Stirdivant S.M., Darke P.L., Kuo L.C (2002) Crystal structure of the apo, unactivated insulin-like growth factor-1 receptor kinase. Implication for inhibitor specificity. J Biol Chem 277 : 38797.
14. Pautsch A., Zoephel A., Ahorn H., Spevak W., Hauptmann R., Nar H. (2001) Crystal structure of bisphosphorylated IGF-1 receptor kinase. Insight into domain movements upon kinase activation. Structure (Cambridge, MA, United States) 9 : 955.
15. Favelyukis S., Till J.H., Hubbard S.R., Miller W.T. (2001) Structure and autoregulation of the insulin-like growth factor 1 receptor kinase. Nat Struct Biol 8 : 1058.
16. Wentzler S., El Ahmad Y., Filoche Romme B., Nemecek C., Venot C. (2005) Fr. Demande 217 pp.; WO2006/037875.
17. Kumar V., Dority J.A., Bacon E.R., Singh B., Lesher G.Y. (1992) Synthesis of 7-azaindole and 7-azaoxindole derivatives through a palladium-catalyzed cross-coupling reaction. J Org Chem 57 : 6997.
18. Koradin C., Dohle W., Rodriguez A.L., Schmid B., Knochel P. (2003) Synthesis of polyfunctional indoles and related heterocycles mediated by cesium and potassium bases. Tetrahedron 59 : 1571.
19. Nemecek C., Metz W., Wentzler S., Lesuisse D. (2006) Fr. Demande 110 pp. WO2005/095399.
20. O'Neill B.T., Yohannes D., Bundesmann M.W., Arnold E.P. (2000) Total synthesis of (+/-)-cytisine. Org Lett 2 : 4201.
21. Sinhababu A.K., Borchardt R.T. (1988) Independent synthesis of 5-hydroxytryptamine-4,7-dione, the neurocytotoxic product of autoxidation of 5,7-dihydroxytryptamine. J Heterocycl Chem 1988 : 25.
22. Rosini G., Ballini R., Sorrenti P. (1983) Synthesis of 2-nitroalkanols on alumina surfaces without solvent: a simple, mild and convenient method. Synthesis 6 : 1014 1016.
23. Henry L. (1895) Formation. synthétique d'alcools nitrés. C R Acad Sci Paris 120 : 1265.
24. Novellino L., d'Ischia M., Prota G. (1999) Expedient Synthesis of 5,6-Dihydroxyindole and Derivatives via an Improved Zn(II)-Assisted 2,b-Dinitrostyrene Approach. Synthesis 5 : 793 796.
25. Sinhababu A.K., Borchardt R.T. (1983) Silica gel-assisted reduction of nitrostyrenes to 2-aryl-2-[2H]-1-nitroethanes with sodium borodeuteride. J Org Chem 48 : 3347.